Prenatal exposure to acetaminophen and asthma in children

Area of Science:

• Perinatal research
• Pediatric epidemiology
• Pharmacovigilance

Background:

• Acetaminophen (paracetamol) is a widely used analgesic and antipyretic during pregnancy.
• Concerns exist regarding potential links between prenatal drug exposure and adverse child health outcomes, including asthma.
• Understanding the safety profile of acetaminophen during pregnancy is crucial for clinical practice.

Purpose of the Study:

• To investigate the association between prenatal acetaminophen exposure and the risk of diagnosed asthma and asthma symptoms in children up to 6 years of age.
• To evaluate if the timing and dosage of acetaminophen use during pregnancy influence asthma risk.
• To provide evidence-based information for pregnant individuals and healthcare providers regarding acetaminophen safety.

Main Methods:

• Prospective cohort study involving 1,505 pregnant women and their children followed until the child's age of 6 years.
• Assessment of acetaminophen use during the first and third trimesters of pregnancy through validated questionnaires.
• Logistic regression models were used to calculate adjusted odds ratios (aORs) for asthma, controlling for potential confounders.

Main Results:

• Acetaminophen was used by 69% of pregnant women in the study cohort.
• Overall prenatal acetaminophen use was not significantly associated with an increased risk of childhood asthma (aOR 0.76; 95% CI 0.53-1.10).
• Use of acetaminophen in both the first and third trimesters showed a significant reduction in asthma risk (aOR 0.59; 95% CI 0.36-0.98), with no clear dose-response relationship.

Conclusions:

• Prenatal exposure to acetaminophen does not appear to elevate the risk of asthma in children.
• Acetaminophen use during both early and late pregnancy may be associated with a protective effect against childhood asthma.
• Further research is warranted to confirm these findings and explore potential biological mechanisms.